http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019185518-A9
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c88d09c0c47c845abf8d53da9ad0592b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4747 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 |
| filingDate | 2018-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cd6d792670688005bb806cff63d8183 |
| publicationDate | 2019-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2019185518-A9 |
| titleOfInvention | Warhead-containing peptidomimetic macrocycles as modulators of bfl-1 |
| abstract | The disclosed peptidomimetic macrocycles modulate the activity of BFL-1 or a BCL-2 family protein. BFL-1, an anti-apoptotic BCL-2 family member, blocks p53-mediated apoptosis and has oncogenic transforming activity. Peptidomimetic macrocycles, pharmaceutical compositions, and methods disclosed herein can be used for the treatment of disease in which BFL-1 or a BCL-2 family protein is over-expressed, such as cancer. In particular, BFL-1-modulating or a BCL-2 family protein-modulating peptidomimetic macrocycles disclosed herein can be applied in the setting of resistance to BCL-2 family inhibitors, which is often engendered by BFL-1 or BCL-2 family protein over-expression or hyper-activation. |
| priorityDate | 2017-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 3134.